Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 98,745 | 162,303 | 177,918 | 169,141 | 167,630 |
| Marketable Securities | 179,145 | 115,505 | 99,323 | 101,298 | 95,111 |
| Receivables | 60,588 | 52,634 | 44,643 | 50,306 | 55,928 |
| Inventories | 43,893 | 46,800 | 50,070 | 54,742 | 60,877 |
| TOTAL | $396,446 | $390,191 | $384,084 | $388,647 | $392,060 |
| Non-Current Assets | |||||
| PPE Net | 17,962 | 18,508 | 18,114 | 18,247 | 18,405 |
| Intangibles | 36,791 | 36,675 | 37,603 | 38,435 | 39,267 |
| Other Non-Current Assets | 48,301 | 45,852 | 43,924 | 46,738 | 44,725 |
| TOTAL | $103,054 | $101,035 | $99,641 | $103,420 | $102,397 |
| Total Assets | $499,500 | $491,226 | $483,725 | $492,067 | $494,457 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,529 | 5,389 | 3,191 | 3,725 | 3,032 |
| Accrued Expenses | 21,443 | 20,733 | 15,489 | 18,054 | 20,035 |
| Other current liabilities | 15,199 | 11,310 | 9,731 | 10,778 | 10,464 |
| TOTAL | $67,663 | $62,797 | $52,379 | $55,566 | $56,226 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,050 | 1,236 | 1,330 | 1,477 | 1,648 |
| Deferred Revenues | 25,492 | 25,365 | 23,968 | 23,009 | 22,695 |
| Other Non-Current Liabilities | 18,952 | 26,943 | 26,829 | 27,246 | 28,387 |
| TOTAL | $36,100 | $42,966 | $42,223 | $43,887 | $45,167 |
| Total Liabilities | $103,763 | $105,763 | $94,602 | $99,453 | $101,393 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 128,097 | 128,811 | 131,506 | 131,273 | 130,824 |
| Common Shares | 129 | 130 | 132 | 131 | 131 |
| Retained earnings | -35,199 | -44,840 | -45,781 | -35,347 | -29,178 |
| Other shareholders' equity | 16 | 101 | -195 | -1,554 | -1,275 |
| TOTAL | $395,737 | $385,463 | $389,123 | $392,614 | $393,064 |
| Total Liabilities And Equity | $499,500 | $491,226 | $483,725 | $492,067 | $494,457 |